Despite the existing therapies and lack of receptors such as HER-2, estrogen receptor and progesterone receptor, triple-negative breast cancer is one of the most aggressive subtypes of breast cancer. TNBCs are known for their highly aggressive metastatic behavior and typically migrate to brain and bone for secondary site propagation. Many diseases share similar molecular pathology exposing new avenues in molecular signaling for engendering innovative therapies. Generation of newer therapies and novel drugs are time consuming associated with very high resources. In order to provide personalized or precision medicine, drug repositioning will contribute in a cost-effective manner. In our study, we have repurposed and used a neoteric combination of two drug molecules namely, fluvoxamine and tivozanib, to target triple-negative breast cancer growth and progression. Our combination regime significantly targets two diverse but significant pathways in TNBCs. Subsequent analysis on migratory, invasive, and angiogenic properties showed the significance of our repurposed drug combination. Molecular array data resulted in identifying the specific and key players participating in cancer progression when the drug combination was used. The innovative combination of fluvoxamine and tivozanib reiterates the use of drug repositioning for precision medicine and subsequent companion diagnostic development.

尽管现有疗法和缺乏受体，如 HER-2、雌激素受体和孕激素受体，三阴性乳腺癌是乳腺癌最具侵袭性的亚型之一。TNBCs 以其高度侵袭性的转移行为而闻名，并且通常迁移到大脑和骨骼以进行次要部位传播。许多疾病具有相似的分子病理学，揭示了用于产生创新疗法的分子信号传导的新途径。更新疗法和新药的产生与非常高的资源相关联是耗时的。为了提供个性化或精准医疗，药物重新定位将以具有成本效益的方式做出贡献。在我们的研究中，我们重新利用并使用了两种药物分子的新组合，即氟伏沙明和替沃扎尼，以靶向三阴性乳腺癌的生长和进展。我们的组合方案显着针对 TNBC 中两种不同但重要的途径。随后对迁移、侵入和血管生成特性的分析显示了我们重新调整用途的药物组合的重要性。当使用药物组合时，分子阵列数据导致识别参与癌症进展的特定和关键参与者。氟伏沙明和 tivozanib 的创新组合重申了将药物重新定位用于精准医学和随后的伴随诊断开发。当使用药物组合时，分子阵列数据导致识别参与癌症进展的特定和关键参与者。氟伏沙明和 tivozanib 的创新组合重申了将药物重新定位用于精准医学和随后的伴随诊断开发。当使用药物组合时，分子阵列数据导致识别参与癌症进展的特定和关键参与者。氟伏沙明和 tivozanib 的创新组合重申了将药物重新定位用于精准医学和随后的伴随诊断开发。